Loading
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Latest quote
$77.28
+$1.18 · +1.55%
After-hours
$77.70
+$0.42 · +0.54%
Oct 8, 7:57 PM ET
Regular session · ET · Market data may be delayed.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Day range
Current $77.28
52-week range
Current $77.28
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
66
Undervalued
Sentiment
45
Mixed
Risk
48
Elevated Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Day range
Current $77.28
52-week range
Current $77.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 642.82M USD | 610.79M USD | 618.73M USD | 516.41M USD | 490.49M USD |
| Cost of goods sold | 198.94M USD | 196.3M USD | 209.41M USD | 120.39M USD | 74.09M USD |
| Gross profit | 443.88M USD | 414.48M USD | 409.31M USD | 396.02M USD | 416.4M USD |
| Research and development | 238.63M USD | 264.7M USD | 270.33M USD | 265.67M USD | 211.75M USD |
| Selling, general, and administrative | 316.13M USD | 344.34M USD | 343.33M USD | 298.3M USD | 257.56M USD |
| Operating expenses | 554.77M USD | 609.04M USD | 674.64M USD | 563.97M USD | 469.31M USD |
| Interest income | 20.05M USD | 18.45M USD | 16.91M USD | 6.65M USD | 206K USD |
| Interest expense | — | 4K USD | 33K USD | 476K USD | 866K USD |
| Depreciation and amortization | 43.82M USD | 43.71M USD | 43.62M USD | 33.01M USD | 28.25M USD |
| Operating income | −110.89M USD | −194.56M USD | −265.33M USD | −167.94M USD | −52.91M USD |
| Net income | −43.54M USD | −182.63M USD | −255.1M USD | −166M USD | −58.22M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 17, 2006 | 1:2 | — | — |
Effective Jul 17, 2006
1:2
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK326.88M2.95%5.56B USD0.75%$87.60-0.79%
iShares Russell 2000 ETFIWM234.07M0.30%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Total Stock Market ETFVTI220.04M0.01%2.3T USD0.03%$379.56-0.39%
ARK Genomic Revolution ETFARKG189.34M8.97%1.56B USD0.75%$49.29-1.70%
Vanguard Morningstar Small-Cap ETFVB159.56M0.09%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK91.58M0.20%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF84.82M0.09%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO83.4M0.59%14.04B USD0.24%$353.47-0.53%ARK Innovation ETFARKKiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
